Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

FVIIa Binding to the Endothelial Protein C Receptor Reduces Protein Recovery in Vivo

Giulia Pavani, MS, Lacramioara Ivanciu, PhD, Paris Margaritis, DPhil

Blood (2012) 120 (21): 18.

https://doi.org/10.1182/blood.V120.21.18.18

Published: 2012

Journal Articles

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Frank M Horling, PhD, Christine Lenk, Rafi Uddin Ahmad, PhD, Markus Weiller, PhD, Maria Schuster, DVM, Hans Peter Schwarz, MD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 3327.

https://doi.org/10.1182/blood.V118.21.3327.3327

Published: 2011

Journal Articles

Employing Factor IX Variants to Avoid Limitations Imposed by Immune Recognition of AAV Vector in Hemophilia B Gene Therapy

Paul E. Monahan, MD, Junjiang Sun, MD, Tong Gui, PhD, David G Wichlan, Scott W McPhee, R. Jude Samulski

Blood (2011) 118 (21): 3124.

https://doi.org/10.1182/blood.V118.21.3124.3124

Published: 2011

Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo

Blood (2010) 116 (21): 3664.

https://doi.org/10.1182/blood.V116.21.3664.3664

Published: 2010

Journal Articles

Functional Characterization of a Recombinant FVIIa Drug Candidate

Peter L Turecek, PhD, Katalin Varadi, PhD, Susanne Vejda, PhD, Ernst Boehm, PhD, Hanspeter Rottensteiner, PhD, Hans Peter Schwarz, PhD, Artur Mitterer, PhD, Wolfgang Mundt, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2010) 116 (21): 4653.

https://doi.org/10.1182/blood.V116.21.4653.4653

Published: 2010

Journal Articles

Off-Label Use of Recombinant Factor VIIa in United States Hospitals: 2000-2008.

Aaron C. Logan, MD, PhD, Veronica Yank, MD, Randall S. Stafford, MD, PhD

Blood (2009) 114 (22): 67.

https://doi.org/10.1182/blood.V114.22.67.67

Published: 2009

Journal Articles

Successful Treatment of Factor IX Inhibitor Complicated by Nephrotic Syndrome with Rituxan.

Jonathan Bernstein, MD, Neepa Gupta, MD, Rebecca Berkowitz, RN

Blood (2007) 110 (11): 3971.

https://doi.org/10.1182/blood.V110.11.3971.3971

Published: 2007

Journal Articles

Novel Treatment Approaches in Combination with Rituximab for Immune Tolerance Induction in Severe Hemophilia B.

Amanda M. Brandow, DO, Rowena C. Punzalan, MD, Karen Stephany, Craig Helsell, Joan C. Gill, MD

Blood (2007) 110 (11): 3975.

https://doi.org/10.1182/blood.V110.11.3975.3975

Published: 2007

Journal Articles

Anti-Factor IX Antibodies Displaying FVIIIa-Like Activity.

Randolf J. Kerschbaumer, Michael Dockal, Rosing Jan, Fritz Scheiflinger

Blood (2006) 108 (11): 1713.

https://doi.org/10.1182/blood.V108.11.1713.1713

Published: 2006

Journal Articles

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Kurt P. Leuenberger, MD, Spero Cataland, MD, Ming Jin, MD, PhD, Carol Orr, Guido Marcucci, MD, Eric H. Kraut, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 2150.

https://doi.org/10.1182/blood.V106.11.2150.2150

Published: 2005

Journal Articles

Hemophilia B Gene Therapy Modelled in Null and Missense Mutant Mice: Kinetics of Transgenic Factor IX Expression Influences Tolerance to a Greater Extent Than Dose or Serotype of Adeno-Associated Virus (AAV) Vector.

Paul E. Monahan, MD, Tai-Ping Zhang, MD, Da-Yun Jin, Tong Gui, MD, PhD, Darrel W. Stafford, PhD

Blood (2005) 106 (11): 5526.

https://doi.org/10.1182/blood.V106.11.5526.5526

Published: 2005

Journal Articles

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

Olivier D. Christophe, Peter J. Lenting, Ghislaine Cherel, Mariette Boon-Spijker, Jean-Maurice Lavergne, Ria Boertjes, Marie-Elisabeth Briquel, Arja de Goede-Bolder, Jenny Goudemand, Solange Gaillard, Roseline d'Oiron, Dominique Meyer, Koen Mertens

Blood (2001) 98 (5): 1416–1423.

https://doi.org/10.1182/blood.V98.5.1416

Published: 2001

Journal Articles

Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity: Presented in part at the 40th Annual Meeting of The American Society of Hematology, Miami Beach, FL.

Jay N. Lozier, Mark E. Metzger, Robert E. Donahue, Richard A. Morgan

Blood (1999) 94 (12): 3968–3975.

https://doi.org/10.1182/blood.V94.12.3968

Published: 1999

Journal Articles

The Rhesus Macaque as an Animal Model for Hemophilia B Gene Therapy

Jay N. Lozier, Mark E. Metzger, Robert E. Donahue, Richard A. Morgan

Blood (1999) 93 (6): 1875–1881.

https://doi.org/10.1182/blood.V93.6.1875.406k16_1875_1881

Published: 1999

Journal Articles

The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors

MW Hilgartner, GL Knatterud

Blood (1983) 61 (1): 36–40.

https://doi.org/10.1182/blood.V61.1.36.36

Published: 1983

Journal Articles

Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction

RM Lewis, HM Reisner, KS Chung, HR Roberts

Blood (1980) 56 (4): 608–614.

https://doi.org/10.1182/blood.V56.4.608.608

Published: 1980

NARROW

FVIIa Binding to the Endothelial Protein C Receptor Reduces Protein Recovery in Vivo

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Employing Factor IX Variants to Avoid Limitations Imposed by Immune Recognition of AAV Vector in Hemophilia B Gene Therapy

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Functional Characterization of a Recombinant FVIIa Drug Candidate

Off-Label Use of Recombinant Factor VIIa in United States Hospitals: 2000-2008.

Successful Treatment of Factor IX Inhibitor Complicated by Nephrotic Syndrome with Rituxan.

Novel Treatment Approaches in Combination with Rituximab for Immune Tolerance Induction in Severe Hemophilia B.

Anti-Factor IX Antibodies Displaying FVIIIa-Like Activity.

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Hemophilia B Gene Therapy Modelled in Null and Missense Mutant Mice: Kinetics of Transgenic Factor IX Expression Influences Tolerance to a Greater Extent Than Dose or Serotype of Adeno-Associated Virus (AAV) Vector.

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

Adenovirus-Mediated Expression of Human Coagulation Factor IX in the Rhesus Macaque Is Associated With Dose-Limiting Toxicity: Presented in part at the 40th Annual Meeting of The American Society of Hematology, Miami Beach, FL.

The Rhesus Macaque as an Animal Model for Hemophilia B Gene Therapy

The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors

Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only